Linden Portfolio Company Virtus Pharmaceuticals Appoints Three Board Directors
Chicago, IL (May 12, 2017) – Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, is pleased to announce that Virtus Pharmaceuticals (“Virtus”) has appointed Yatindra Joshi, Vinod Melvani, and Christopher Worrell as Directors of the Board.
Yatindra Joshi is a global pharmaceutical executive with more than 30 years of product development experience. Most recently, Mr. Joshi was the Senior Vice President of Research and Development at Teva Pharmaceutical Industries, where he led the North American development team focused on generic and 505(b)(2) pharmaceutical products. Prior to that, Mr. Joshi led the U.S. pharmaceutical and analytical group at Novartis, where he oversaw product development for global markets. Mr. Joshi has also held leadership positions at Bristol Meyers Squibb and Gensia Laboratories.
Vinod Melvani is a senior pharmaceutical executive with a background in supply chain, strategic sourcing, and commercialization. Mr. Melvani has more than 25 years of experience covering pharmaceuticals, payers, and providers. Most recently, Mr. Melvani led McKesson’s Generics business in the U.S. with full P&L responsibility. His prior roles at McKesson spanned global sourcing, pricing, and business development. Earlier in his career, Mr. Melvani held management consulting positions at Deloitte and Medimetrix.
Christopher Worrell is a seasoned generic pharmaceutical executive with a proven track record of driving growth in private equity-backed pharmaceutical businesses. Mr. Worrell served as Chief Executive Officer of CorePharma and Amedra Pharmaceuticals and successfully sold those businesses to Impax Laboratories in 2015. Prior to his role at CorePharma and Amedra Pharmaceuticals, Mr. Worrell served as President and Chief Executive Officer of Cadista Pharmaceuticals and held executive roles with Cardinal Health and Sandoz.
“Linden is thrilled to have these three talented executives join the Virtus Board,” said Linden President and Managing Partner and Virtus Chairman, Tony Davis. “They bring multi-faceted expertise in the generic pharmaceutical industry that will accelerate growth and drive the value creation plan at Virtus.”
Tina Guilder, CEO of Virtus, said, “We are very excited to welcome Yatindra, Vinod, and Chris to the Board. Their experience and perspective will be invaluable to Virtus as we execute our strategy over the coming years.”
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches, and outstanding customer service. For more information, please visit www.virtusrx.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.